SIGA shares shoot up on potential US biodefence contract
This article was originally published in Scrip
Executive Summary
Shares of biodefence company SIGA Technologies closed 46% up at $12.47 (13 October) on news that the US Department of Health and Human Services (HHS) intends to award it a contract worth up to $2.8 billion for the delivery of 1.7 million courses of its smallpox vaccine for the strategic national stockpile.